Abstract:Despite decades of efforts, non-small-cell lung cancer (NSCLC) remains the leading cause of cancer mortality globally primarily due to the challenge in early detection of the cancer. Being an important player in cancer development, the dysregulated miRNAs have been shown promising values as non-invasive diagnostic and prognostic biomarkers for NSCLC. The aim of our study is to access the efficacy and reliability of a potential circulating miRNA panel in early diagnosis of NSCLC. We first selected eight candidate miRNAs, miR-146b, miR-205, miR-29c, miR-31, miR-30b, miR-337, miR-411, and miR-708, which have been shown frequently aberrant in primary NSCLC patients based on our previous studies and other reports. The serum level of each of these miRNAs was evaluated by quantitative real-time PCR (qRT-PCR) in training and testing sets. We found that 5 out of 8 miRNAs (miR-146b, miR-205, miR-29c, miR-30b, and miR-337) were significantly up- regulated in NSCLCs patients compared to healthy or cancer-free controls in both training and testing sets. Based on the logistic regression model, a 4-miRNAs set (miR-146b, miR- 205, miR-29c and miR-30b) was picked out of the 5 miRNAs owing to its excellent diagnostic power for NSCLC patients in the training set (AUC=0.99, accuracy=95.00%), the testing set (AUC=0.93, accuracy=89.69%), and the training-testing combined set (AUC=0.96, accuracy=92.00%). When pathological subtypes of NSCLC are compared, this 4-miRNA panel carried a relatively higher prediction power and higher sensitivity for adenocarcinoma (AC) (AUC=0.98, sensitivity=99.10%) than for squamous cell carcinoma (SCC) (AUC=0.93, sensitivity=90.32%). Additionally, this panel demonstrated a comparable diagnostic capacity for stage I (AUC=0.96) and stage II-III (AUC=0.95) of NSCLC, suggesting its role in reflecting the tumor load. Importantly, the high levels of miR-146b and miR-29c in serum were significantly associated with poor 5-year overall survival (OS) (both p=0.04). Further survival analysis showed that high level of miR-146b in serum is specifically correlated with poor survival rate in SCC patients (p=0.0035) but not in AC patients (p=0.83), consistent with our previous finding that the high tissue expression of miR-146b in lung cancer specimen is indicative of a poor prognosis for SCC patients. Altogether, our study demonstrated that the 4-miRNA panel is a novel, sensitive and non-invasive serum marker for the early diagnosis of NSCLC.

Serum Microrna-155 As A Potential Biomarker To Track Disease In Breast Cancer

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

Increased Circulating Microrna-155 As a Potential Biomarker for Breast Cancer Screening: a Meta-Analysis.

Identification of Serum Mir-1915-3p and Mir-455-3p As Biomarkers for Breast Cancer.

Appraising MicroRNA-155 as a Noninvasive Diagnostic Biomarker for Cancer Detection: A Meta-Analysis.

Serum Microrna As Potential Biomarker to Detect Breast Atypical Hyperplasia and Early-Stage Breast Cancer.

Investigation of Microrna-155 As a Serum Diagnostic and Prognostic Biomarker for Colorectal Cancer

Serum Microrna Profiling and Breast Cancer Risk: the Use of Mir-484/191 As Endogenous Controls

Circulating Microrna-92A and Microrna-21 As Novel Minimally Invasive Biomarkers for Primary Breast Cancer

Predicting distant metastasis and chemoresistance using plasma miRNAs

Serum Exosomal miR-17-5p as a Promising Biomarker Diagnostic Biomarker for Breast Cancer

Serum Mirna-1 May Serve As a Promising Noninvasive Biomarker for Predicting Treatment Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Serum Microrna Signature Is Capable Of Early Diagnosis For Non-Small Cell Lung Cancer

A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer

Diagnostic Value Of Circulating Mir-155, Mir-21, And Mir-10b As Promising Biomarkers In Human Breast Cancer

Abstract 1477: Circulating miR-125a-3p and miR-451a may be liquid biopsy biomarkers for the diagnosis of breast cancer

Identification of Microrna Biomarkers in the Blood of Breast Cancer Patients Based on Microrna Profiling.

Decreased Serum Mir-181a Is A Potential New Tool For Breast Cancer Screening

Clinical importance of serum miRNA levels in breast cancer patients

Branched Rolling Circle Amplification Method for Measuring Serum Circulating Microrna Levels for Early Breast Cancer Detection

Serum Microrna Expression Profile As A Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer